BioProgress, the speciality pharmaceutical and healthcare company, has announced the creation of a new executive operational board, and the appointment of Keith Hemming, as head of operations in a new position within the management team of the company.
The operational board will be responsible for the day-to-day management of the group.
Hemming has over twenty years experience in the pharmaceutical industry, holding senior marketing and general management positions with Squibb, Yamanouchi, and most recently as president of UK operations for Fujisawa Pharma, member of the Fujisawa European senior management team. Prior to this he was with Astellas Pharmaceuticals working on European strategy and implementation. He has launched Flomax and Protopic in the UK, and took Prograf, an immunosuppressant, to market leadership.
Keith was a member of the Board of Management of the Association of British Pharmaceutical Industry (ABPI) for four years, and member of the UK Pharmaceutical Code of Practice Appeal Board.
He was also founder and first chair of the UK Japanese Pharmaceutical Group, and chair of the Industry Group for the National Health Service Framework for Renal Services.
